Publikationen – Universitäts-Hautklinik Tübingen
Universitäts-Hautklinik Tübingen

Eine aktuelle Literaturliste der Mitarbeiter der Hautklinik Tübingen finden Sie in der Literatur-Datenbank PubMed.

Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, Maio M (2017) Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 18: 611-622.

Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K (2017) Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18: 435-445.

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF, for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform , Gershenwald JE, Scolyer RA, Atkins MB, Balch CM, Barnhill RL, Bilimoria KY, Buzaid AC, Byrd DR, Cochran AJ, Eggermont AMM, Elder DE, Faries MB, Flaherty KT, Garbe C, Gardner JM, Gimotty PA, Halpern AC, Haydu LE, Hess KR, Johnson TM, Kirkwood JM, Lazar AJ, Lee AWM, Long GV, McArthur GA, Mihm MC, Prieto VG, Ross MI, Sober AJ, Sondak VK, Thompson JF, Wong SL, Delman KA, Santinami M, Maurichi A, Nagore E, Faries MB, Thompson JF, Scolyer RA, McArthur GA, Gyorki DE, Henderson M, Stratigos AJ, Gogas H, Gershenwald JE, Haydu LE, Rossi CR, Sommariva A (2017) Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67: 472-492.

Heppt MV, Schlaak M, Eigentler TK, Kähler KC, Kiecker F, Loquai C, Meier F, Tomsitz D, Brenner N, Niesert AC, Thonke R, Hauschild A, Berking C (2017) Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. Ann Oncol 28: 3104-3106.

Heratizadeh A, Werfel T, Wollenberg A, Abraham S, Plank-Habibi S, Schnopp C, Sticherling M, Apfelbacher C, Biedermann T, Breuer K, Fell I, Fölster-Holst R, Heine G, Grimm J, Hennighausen L, Kugler C, Reese I, Ring J, Schäkel K, Schmitt J, Seikowski K, von Stebut E, Wagner N, Waßmann-Otto A, Wienke-Graul U, Weisshaar E, Worm M, Gieler U, Kupfer J, Arbeitsgemeinschaft Neurodermitisschulung für Erwachsene (ARNE) Study Group , Brauner K, Dölle S, Ehmann L, Hagmaier U, Eberlein S, Kroth J, Lämmerhirt K, Landleiter R, Lorenz U, Lüdemann A, Matterne U, Mitzel-Rink H, Niebuhr M, Rehberg T, Vogel S, Wichmann K (2017) Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial. J Allergy Clin Immunol 140: 845-853.e3.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L (2017) Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun 8: 592.

Krause K, Tsianakas A, Wagner N, Fischer J, Weller K, Metz M, Church MK, Maurer M (2017) Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. J Allergy Clin Immunol 139: 1311-1320.

Liu X, Pichulik T, Wolz OO, Dang TM, Stutz A, Dillen C, Delmiro Garcia M, Kraus H, Dickhöfer S, Daiber E, Münzenmayer L, Wahl S, Rieber N, Kümmerle-Deschner J, Yazdi A, Franz-Wachtel M, Macek B, Radsak M, Vogel S, Schulte B, Walz JS, Hartl D, Latz E, Stilgenbauer S, Grimbacher B, Miller L, Brunner C, Wolz C, Weber AN (2017) Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. J Allergy Clin Immunol 140: 1054-1067.e10.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ (2017) Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 28: 1631-1639.

Mamantopoulos M, Ronchi F, Van Hauwermeiren F, Vieira-Silva S, Yilmaz B, Martens L, Saeys Y, Drexler SK, Yazdi AS, Raes J, Lamkanfi M, McCoy KD, Wullaert A (2017) Nlrp6- and ASC-Dependent Inflammasomes Do Not Shape the Commensal Gut Microbiota Composition. Immunity 47: 339-348.e4.

McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K (2017) Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol 28: 634-641.

Nus M, Sage AP, Lu Y, Masters L, Lam BYH, Newland S, Weller S, Tsiantoulas D, Raffort J, Marcus D, Finigan A, Kitt L, Figg N, Schirmbeck R, Kneilling M, Kneilling M, Yeo GSH, Binder CJ, de la Pompa JL, Mallat Z (2017) Marginal zone B cells control the response of follicular helper T cells to a high-cholesterol diet. Nat Med 23: 601-610.

Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, Real B, Bielefeld N, Howe S, Weide B, Gutzmer R, Utikal J, Loquai C, Gogas H, Klein-Hitpass L, Zeschnigk M, Westendorf AM, Trilling M, Horn S, Schilling B, Schadendorf D, Griewank KG, Paschen A (2017) Acquired IFN? resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun 8: 15440.

Thunemann M, Schörg BF, Feil S, Lin Y, Voelkl J, Golla M, Vachaviolos A, Kohlhofer U, Quintanilla-Martinez L, Olbrich M, Ehrlichmann W, Reischl G, Griessinger CM, Langer HF, Gawaz M, Lang F, Schäfers M, Kneilling M, Kneilling M, Pichler BJ, Feil R (2017) Cre/lox-assisted non-invasive in vivo tracking of specific cell populations by positron emission tomography. Nat Commun 8: 444.

Warren RB, Mrowietz U, von Kiedrowski R, Niesmann J, Wilsmann-Theis D, Ghoreschi K, Zschocke I, Falk TM, Blödorn-Schlicht N, Reich K (2017) An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389: 528-537.

Eigentler TK, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D, Hölzle E, Kiecker F, Becker J, Sunderkötter C, Moll I, Richtig E, Pönitzsch I, Pehamberger H, Kaufmann R, Pföhler C, Vogt T, Berking C, Praxmarer M, Garbe C, Dermatologic Cooperative Oncology Group (DeCOG) (2016) Adjuvant treatment with pegylated interferon ?-2a versus low-dose interferon ?-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. Ann Oncol 27: 1625-32.

Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp HG, Behringer DM, Ko YD, Hilger RA, Roessler M, Kloft C, Henrich A, Moritz B, Miller MC, Salamone SJ, Jaehde U (2016) Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 27: 1895-902.

Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM, Yamazaki T, Roberti MP, Daillère R, Vétizou M, Poirier-Colame V, Semeraro M, Caignard A, Slingluff CL, Sallusto F, Rusakiewicz S, Weide B, Marabelle A, Kohrt H, Dalle S, Cavalcanti A, Kroemer G, Di Giacomo AM, Maio M, Wong P, Yuan J, Wolchok J, Umansky V, Eggermont A, Zitvogel L (2016) Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest 126: 921-37.

Frick M, Fischer J, Helbling A, Ruëff F, Wieczorek D, Ollert M, Pfützner W, Müller S, Huss-Marp J, Dorn B, Biedermann T, Lidholm J, Ruecker G, Bantleon F, Miehe M, Spillner E, Jakob T (2016) Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy. J Allergy Clin Immunol 138: 1663-1671.e9.

Kaesler S, Skabytska Y, Chen KM, Kempf WE, Volz T, Köberle M, Wölbing F, Hein U, Hartung T, Kirschning C, Röcken M, Biedermann T (2016) Staphylococcus aureus-derived lipoteichoic acid induces temporary T-cell paralysis independent of Toll-like receptor 2. J Allergy Clin Immunol 138: 780-790.e6.

Clément M, Basatemur G, Masters L, Baker L, Bruneval P, Iwawaki T, Kneilling M, Kneilling M, Yamasaki S, Goodall J, Mallat Z (2016) Necrotic Cell Sensor Clec4e Promotes a Proatherogenic Macrophage Phenotype Through Activation of the Unfolded Protein Response. Circulation 134: 1039-1051.

Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17: 1248-60.

Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkötter C, Kaatz M, Schulte KW, Lehmann P, Vogt T, Ulrich J, Herbst R, Gehring W, Simon JC, Keim U, Martus P, Garbe C, German Dermatologic Cooperative Oncology Group (DeCOG) (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17: 757-67.

Zipperer A, Konnerth MC, Laux C, Berscheid A, Janek D, Weidenmaier C, Burian M, Schilling NA, Slavetinsky C, Marschal M, Willmann M, Kalbacher H, Schittek B, Brötz-Oesterhelt H, Grond S, Peschel A, Krismer B (2016) Human commensals producing a novel antibiotic impair pathogen colonization. Nature 535: 511-6.

Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, Papadakis K, Pope J, Matucci-Cerinic M, Furst DE, DUAL-1 Investigators , DUAL-2 Investigators , Zochling J, Stevens W, Proudman S, Feenstra J, Youssef P, Soroka N, Tyabut T, Mikhailova EI, Rashkov R, Batalov A, Yablanski K, Keystone E, Pope J, Jones N, Dunne J, Masetto A, Calabresse RJ, Cabezas PC, Silva MO, Sariego IA, Escalente WJ, Ani? B, Kaliterna DM, Morovi?-Vergles J, Novak S, Prus V, Artukovi? M, Soukup T, Be?va? R, Fojtík Z, Mouthon L, Kollert F, Krieg TM, Riemekasten G, Lahner N, Fierlbeck G, Ahmadi-Simab K, Diehm C, Szücs G, Kumánovics G, Nagy G, Pal S, Veeravalli SC, Danda D, Ferri C, Cerinic MM, Cozzi F, Ferraccioli G, Wiland P, Rudnicak L, Zwolak R, Roszkiewicz J, Oleynikov V, Nikulenkova N, Lesnyak O, Kaydashev I, Kurytar O, Piura O, Chopyak V, Chatterjee S, Furst DE, Hsu V, Hummers L, Martin R, Domsic R, Schiopu E, Khanna D, Shanahan J, Murphy FT, Kaine J, Davis W, Grau R, Eimon A, Catoggio LJ, Laborde HA, Caeiro F, Savio VG, Amitrano CB, Vanthuyne M, Zeng X, Zhang X, Zhu P, Velásquez-Franco CJ, Choueka PS, Sanchez PJ, Hermann W, Sticherling M, Steinbrink K, Hein R, Aschoff R, Sfikakis P, Settas L, Fraser A, Veale D, Balbir-Gurman A, Lidar M, Litinsky I, Levy Y, Carrillo-Vazquez SM, Rodriguez-Reyna T, Medrano-Ramirez G, Morales-Torres J, Pacheco-Tena CF, Sanchez-Ortiz A, Vonk MC, Stebbings S, Solanki K, Steele R, Ng KP, Zubrzycka-Sienkiewicz A, Brzosko M, Szepietowski JC, Hrycaj P, da Silva IF, dos Santos Lda C, Coelho PJ, Rios G, Chernykh T, Grunina E, Stanislav M, Ally M, Kalla A, Birlik AM, Kovalenko V, Petrov A, Shevchuk S, Stanislavchuk M, Anderson M, Denton CP, Herrick A, Belch J, Chung L, Csuka ME, Frech T, Goldberg A, Kahaleh B, Mayes MD, Rothfield N, Simms RW, Spiera R, Steen V, Varga J, Sikes D, Derk CT, Merkel PA, Kohen MD (2016) Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. JAMA 315: 1975-88.

Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Lafyatis R, Stifano G, Spotswood H, Chen-Harris H, Dziadek S, Morimoto A, Sornasse T, Siegel J, Furst DE (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387: 2630-40.

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M, SOLO 1 and SOLO 2 Investigators , Nikolova-Pavlova E, Stoyanova B, Vlaeva T, Alavi A, Gauvreau G, Henein S, Poulos E, Yang W, Lepage F, Wiseman M, Bissonnette R, Agner T, Deleuran M, Jemec G, Skov L, Kingo K, Konno P, Pender K, Põder A, Vahlberg A, Oksman R, Pasternack R, Remitz A, Bieber T, Dominicus R, Gerlach B, Kardorff B, Toader AL, Kleinheinz A, Gellrich S, Kreutzer K, Leitz N, Offers M, Pauser S, Radtke M, Roloff E, Rosenbach T, Schwarz B, Sell S, Simon JC, Staubach P, Weigel US, Werfel T, Wohlrab J, Wollenberg A, Rothenberger C, Walter A, Yazdi A, Aihara M, Hide M, Kataoka Y, Katoh N, Kawashima M, Kobayashi S, Mitsui H, Nakahara T, Saeki H, Sueki H, Arai S, Ikeda M, Kabashima K, Kawachi Y, Kume A, Moriwaki S, Natsuaki Y, Ogata F, Omi T, Seishima M, Sugaya M, Tsukamoto K, Tsuruta D, Urano S, Watanabe D, Yoshioka A, Furukawa F, Katoh A, Ang CC, Aw DC, Tang M, Lee HY, Orpinell FB, Hernández GC, De La Cueva P, Foraster CF, Iranzo P, Serra AJ, Luna PL, Moya SM, Ramírez DM, Muñoz JP, Carazo JS, Soong W, Hull C, Johnson S, Bhatia N, Limova M, Raikhel M, Sher L, Sofen H, Spector S, Tan R, Yamauchi P, Weber R, Kimura S, Nelson C, Randhawa S, Rendon M, Trevino M, Ling M, Rice Z, Silverberg J, Siri D, Fretzin S, Fowler JF, Boh E, Merola J, Murakawa G, Korenblat P, Campbell J, Bagel J, Beck L, Hazan C, Kalb R, Smith C, Bardelas J, Gawchik S, Schenkel E, Krause R, Allison D, Browning J, Davis S, Lee M, Duffin K, Fisher CT, Pariser D, Gower RG, Adams S, Sapijaszko MJ, Wasel N, Albrecht L, Hong CH, Gulliver W, Landells I, Adam D, Gooderham M, Lomaga M, Lynde C, Rosoph L, Raman M, Robern M, Sapra S, Toth D, Poulin Y, Bagot M, Barbarot S, Grob JJ, Guillet G, Lacour JP, Khemis A, Misery L, Staumont-Sallé D, Brüning H, Darsow U, Ekanayake-Bohlig S, Herbst R, Hoffmann M, Homey B, Niesmann J, Pinter A, Radny P, Reich K, Sattler G, Sebastian M, Thaçi D, Weidinger S, Wildfeuer T, Worm M, Chan H, Chan J, Amerio P, Carlesimo M, Di Lernia V, Emilia R, Didona B, Fargnoli M, Ferrucci SM, Naldi L, Papini M, Parodi A, Pellacani G, Peris K, Pimpinelli N, Romanelli M, Talamonti M, Bylaite-Bucinskiene M, Cesiene J, Narbutas R, Sidlauskiene RB, Adamski Z, Bystrzanowska D, Dyczek A, Hofman T, Leszniewska L, Nowicki R, Owczarek W, Slowinska M, Sobieszek-Kundro A, Weglowska J, Zakrzewski M, Ahn HH, Ahn KJ, Chang SE, Choi GS, Kim MB, Kim KH, Lee KH, Park YM, Park CW, Park GH, Nahm DH, Park YL, Roh J, Seo SJ, Ameen M, Ardern-Jones M, Bewley A, Cooper H, Cork MJ, Guha-Niyogi B, Khan M, Marshall M, Foerster J, Smith C, Appell M, Elewski B, Haynes S, Jazayeri SS, Crowley J, Dhawan S, Ellis M, Kim S, Meltzer S, Mitchell J, Pearlman D, Moss J, Ehrlich A, Forman S, Kuttner B, Penate F, Vaca C, Hamilton T, Paull W, Weisman J, Glazer S, Mehlis S, Guenthner S, Lockshin B, Kimball A, Rosmarin D, Pickett-Baisden T, Halverson P, Kaiser H, Martin A, Stone M, Davis K, Mirkil V, Nossa R, Bretton E, Alexis A, Guttman-Yassky E, Peredo M, Weinberg J, Fleischer A, George R, Lugo-Somolinos A, Nasir A, Hussain I, Blauvelt A, Simpson E, Kalafer M, Hampton M, Humeniuk JM, Rupp N, Carrasco D, MacGillivray B, Moore A, Teller C, Tyring S, Harris D, Jenkin P (2016) Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 375: 2335-2348.

Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R, OPT Compare Investigators , Kogan NN, Schmuth M, Hintner H, Ghislain PD, Alendar F, Kadurina M, Marina S, Kuzeva V, Gospodinov D, Tsankov N, De La Cruz C, Valdes P, Guglielmetti A, Yeung CK, Chun-Yin J, Moreno E, Rojas RF, Melendez EM, Castillo D, Mejia H, Londono AM, Bulic SO, Ceovic R, Biljan D, Pizinger K, Horazdovsky J, Filipovska O, Ettler K, Arenberger P, Iversen L, Bang B, Otkjaer A, Dreno B, Guillet G, Misery L, Aubin F, Reguiai Z, Goujon-Henry C, Bedane C, Paul C, Ortonne JP, Cambazard F, Cuny JF, Schmutz JL, Saiag P, Descamps V, Celerier P, Dominicus R, Enk A, Ring J, Augustin M, Thaci D, Sebastian M, Hoffmann M, Philipp S, Roecken M, Miehe M, Schopf R, Sticherling M, Wozel G, Haase I, Streit V, Kemeny L, Remenyik E, Bakos N, Hollo P, Karolyi Z, Youn JI, Lee MG, Prens EP, Bracke AY, Spuls PI, Eleonore V, Van de Walle KM, Wielowieyska-Szybinska D, Adamski Z, Roszkiewicz J, Wasik G, Janczylo-Jankowska M, Perlamutrov Y, Samtsov AV, Sonin D, Temnikov VE, Danilov S, Sukharev AV, Stetsiouk OU, Kubanova A, Tay YK, Theng CT, Zelenkova H, Urbancek S, Raffayova H, Romero IB, Sanchez Carazo JL, Lopez Estebaranz JL, Sanchez Perez J, Suarez Martin E, Vanaclocha Sebastian F, Hagstromer L, Talme T, Svensson A, Hallander A, Eriksson T, Anliker MD, Ergun T, Ozkan AS, Yazici AC, Ozarmagan G, Bewley AP, Burd R (2015) Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 386: 552-61.

Feucht J, Opherk K, Lang P, Kayser S, Hartl L, Bethge W, Matthes-Martin S, Bader P, Albert MH, Maecker-Kolhoff B, Greil J, Einsele H, Schlegel PG, Schuster FR, Kremens B, Rossig C, Gruhn B, Handgretinger R, Feuchtinger T (2015) Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 125: 1986-94.

Griessinger CM, Maurer A, Kesenheimer C, Kehlbach R, Reischl G, Ehrlichmann W, Bukala D, Harant M, Cay F, Brück J, Nordin R, Kohlhofer U, Rammensee HG, Quintanilla-Martinez L, Schaller M, Röcken M, Pichler BJ, Kneilling M, Kneilling M (2015) 64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET. Proc Natl Acad Sci U S A 112: 1161-6.

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 investigators , Kerr DJ, Birbara C, Ko WT, Koltun WD, Dosik JS, Lewis D, Ehrlich A, Strober BE, George RE, Gillum P, Hamilton TK, Hoekstra JA, Abramovits W, Lebwohl MG, Lee PC, Podda M, Rieken T, Grigat C, Norgauer J, Carus CG, Wozel G, Koerber A, Rosenbach T, Chodorowska G, Maleszka R, Kaszuba A, Rudnicka L, Szymanska EB, Klujszo E, Nowicki R, Wasik G, Thorla IH, Moore A, Grande K, Sobell JM, Lockshin B, Humeniuk JM, Rankin BG, Delamo JG, Pariser DM, Leonardi CL, Davis SA, Ferris LK, Rendon MI, Weisman JD, Fromowitz JS, Jazayeri S, Nossa R, Solovan C, Mihalache D, Tiplica GS, Zbranca-Toporas A, Florea I, Beti H, Wainwright N, Griffiths C, McBride S, Burden D, Foerster J, Butt A, Messenger A, Lim A, Su J, Hall S, Cooper A, Parish LC, Carrasco DA, McCune MA, Werschler WP, Belasco KT, Marcadis A, Gardner TL, Guenthner ST, Nelson CG, Barankin B, Albrecht L, Gooderham M, Poulin Y, Rosoph L, Gauthier JS, Vender R, Wasel N, Sidhu S, Rubel D, Foley P, Spelman L, Bodokh I, Duval-Modeste AB, Guillet G, Paul C, Lacour JP, Aubin F, Chaby G, Grob JJ, Van de Kerkhof P, Ziekenhuis A, de Kort W, Van Doorn MB, Riedl E, Strohal R, Schmuth M, Salmhofer W, Lasko B, Toma A, Woolner D, Barber K, Guenther L, Lynde C, Hanna S, Gupta A, Kunynetz R, Hoffmann M, Werfel T, Reich K, Brau B, Ghoreschi K, Moessn R, Arenberger P, Vasku V, Machovcova A, Ferrandiz C, Bran Eduardo L, Puig Sanz L, Herrera Ceballos E, Lopez Estebaranz J, Belinchon Romero I, Pujol R, Vanaclocha Sebastian F, Carretero Hernandez G, Ferrandiz Pulido L, Blauvelt A, Bukhalo M, Stoll D, Crowley J, Helfrich Y, Miller S, Rafal E, Solomon J, Schleicher S, Schlessinger J, Sofen H, Draelos ZD, Woodson J, Stoessel J, Konig H, Bruning H, Piechatzek R, Lohrbacher-Kozak I, Contzen C, Khariouzov A, Heymer P, Kreutzmann K, Ockenfels HM, Wildfeuer T, Virchow R, Wildfeuer T, Reinhold U, Kurzen H, Termeer C, Rothhaar A, Radny P, Coggi J, Lenz J, Kuettel K, Galal S, Tschen E, Gilboa R, Fretzin S, Fleischer A, Forsha D, Knoepp T, Nahm W, Mehlis S, Menter M, Yamauchi P, Savin R, Gellrich S, Kardorff B, Rütter A, Rütter A, Ludolph-Hauser D, Sebastian M, Tsianakas A, Wolf D, Ludwig-Peitsch W, Philipp S, Augustin M, Yankova R, Kazandjieva J, Tsingov I, Vlaeva T, Sadick N, Fowler J, Truett A, Wu J, Bernhardt M, Lee M, Bagel J, Behringer F, Kircik L, Alonso-Llamazares J, Hole S, Rich P, Gordon K, Campbell J, Kadurina M, Poznanska M, Rajzer L, Padlewska K, Gonzalez Soto RF, Gonzalez JA, Kemeny L, Remenyik E, Karolyi Z, Bakos N, Nemes E, Kovago L, Telegdy E, Callis-Duffin K, Gottlieb A, Soung J, Armstrong A, Norris D, Thomas R, Adams S, Papp K, Langley R, Delorme I, Robern M, Zhou Y, Tan J, Raman M, Sharma S, Maari C, Gyulai R, Varszegi D, Orojan I, Piroska D, Vincze I, Melegh E, Cholmy K, Perlamutrov YN, Kray K, Murashkin N, Sukharev A, Edin A, Smirnova Y, Rudinskiy K, Popp G, Vanscheidt W, Medizin F, Wolfgang J, Kaufmann R, Thaci D, Benoit S, Thron A, Kast P, Studien K, Kaatz M, Schopf R, Theis E, Paschen C, Stratmann L, Graefe A, Kreutzmann K, Degtyareva E, Raznatovskiy K, Stetsiouk O, Givirovskiy S, Chizhov P, Valenzuela F, Fernandez , Gonzalez P, Galimberti RL, Magarinos GA (2015) Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 386: 541-51.

Guenova E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M, Kim KW, Park JH, Seo JH, Ignatova D, Cozzio A, Levesque MP, Volz T, Köberle M, Kaesler S, Thomas P, Mailhammer R, Ghoreschi K, Schäkel K, Amarov B, Eichner M, Schaller M, Clark RA, Röcken M, Biedermann T (2015) IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci U S A 112: 2163-8.

Hauschild A, Garbe C (2015) Immunotherapy: Combined immunotherapy–a new standard in metastatic melanoma? Nat Rev Clin Oncol 12: 439-40.

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386: 444-51.

Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM (2015) Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol 16: 15-7.

Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD (2015) Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33: 1191-6.

Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JH, Fierlbeck G, Genth E, Guenther C, Hein R, Henes J, Herich L, Herrgott I, Koetter I, Kreuter A, Krieg T, Kuhr K, Lorenz HM, Meier F, Melchers I, Mensing H, Mueller-Ladner U, Pfeiffer C, Riemekasten G, Sárdy M, Schmalzing M, Sunderkoetter C, Susok L, Tarner IH, Vaith P, Worm M, Wozel G, Zeidler G, Hunzelmann N, and all participating DNSS centers , Ahrazoglu NM, Becker MO, Mierau R, Neeck G, Fiehn C, Juche A, Rubbert A, Weber M, Fischer-Betz R, Sticherling M, Burkhardt H, Koehm M, Seitz CS, Herink C, Foeldvári I, Norgauer J, Schoeffel D, Renner R, Ziemer M, Steinbrink K, Stadler R, Müller V, Ziai M, Karrer S, Landthaler M, Meyringer R, Buslau M, Tomsitz D, Lee HH, Lehmann P, Gaebelein-Wissing N, Wagner M, Ebel J, Beyer C, Varga R, Bretterklieber A, Reichenberger F, Himsel A (2015) Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 74: 730–737.

Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS (2015) Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov 5: 264-73.

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O’Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16: 908-18.

Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A 112: 6140-5.

Schleicher RI, Reichenbach F, Kraft P, Kumar A, Lescan M, Todt F, Göbel K, Hilgendorf I, Geisler T, Bauer A, Olbrich M, Schaller M, Wesselborg S, O’Reilly L, Meuth SG, Schulze-Osthoff K, Gawaz M, Li X, Kleinschnitz C, Edlich F, Langer HF (2015) Platelets induce apoptosis via membrane-bound FasL. Blood 126: 1483-93.

Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350: 207-11.

De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, Xu D, Zimmer S, Lahrmann C, Schildberg FA, Vogelhuber J, Kraut M, Ulas T, Kerksiek A, Krebs W, Bode N, Grebe A, Fitzgerald ML, Hernandez NJ, Williams BR, Knolle P, Kneilling M, Kneilling M, Röcken M, Lütjohann D, Wright SD, Schultze JL, Latz E (2014) High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol 15: 152-60.

Feil S, Fehrenbacher B, Lukowski R, Essmann F, Schulze-Osthoff K, Schaller M, Feil R (2014) Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circ Res 115: 662-7.

Fischer J, Hebsaker J, Caponetto P, Platts-Mills TA, Biedermann T (2014) Galactose-alpha-1,3-galactose sensitization is a prerequisite for pork-kidney allergy and cofactor-related mammalian meat anaphylaxis. J Allergy Clin Immunol 134: 755-759.e1.

Kaesler S, Volz T, Skabytska Y, Köberle M, Hein U, Chen KM, Guenova E, Wölbing F, Röcken M, Biedermann T (2014) Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10. J Allergy Clin Immunol 134: 92-9.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group , FIXTURE Study Group , Galimberti R, Parra V, Cas ID, Kogan N, Papp K, Vender RB, Bourcier M, Gratton D, Gooderham M, Melendez E, Jaller A, Otero W, Cortes C, Kingo K, Konno P, Pender K, Nurm K, Sigurgeirsson B, Ziv M, Pavlovsky L, Pavlotsky F, Saeki H, Okubo Y, Morita A, Iizuka H, Etoh T, Asano Y, Hori K, Ohi T, Sei Y, Nakayama J, Katoh N, Nemoto O, Igarashi A, Hashimoto T, Abe M, Takae Y, Asahina A, Mabuchi T, Demidova T, Mikazans I, Karls R, Septe M, Stonkus S, Valiukeviciene S, Narbutas R, Bylaite M, Barba J, Ocampo J, Dorantes GL, Maldonado C, Hsu CJ, Tsai TF, Wu NL, Hampton M, Krell J, Rich P, Blauvelt A, Pariser D, Adsit S, Takahashi S, Sofen H, Tichy E, Cather J, Tyring S, Jarratt M, Jones T, Tu J, Kircik L, Gelfand J, Helfrich Y, Swinyer L, Kivitz A, Horowitz D, Klas P, Elewski B, Weiss J, Schlessinger J, Samady J, Menter A, Jazayeri S, Moore J, Marmur E, Fowler J, Giessel M, Galimberti R, Parra V, Cas ID, Kogan N, Papp K, Vender RB, Bourcier M, Gratton D, Gooderham M, Melendez E, Jaller A, Otero W, Cortes C, Kingo K, Konno P, Pender K, Nurm K, Sigurgeirsson B, Ziv M, Pavlovsky L, Pavlotsky F, Saeki H, Okubo Y, Morita A, Iizuka H, Etoh T, Asano Y, Hori K, Ohi T, Sei Y, Nakayama J, Katoh N, Nemoto O, Igarashi A, Hashimoto T, Abe M, Takae Y, Asahina A, Mabuchi T, Demidova T, Mikazans I, Karls R, Septe M, Stonkus S, Valiukeviciene S, Narbutas R, Bylaite M, Barba J, Ocampo J, Dorantes GL, Maldonado C, Hsu CJ, Tsai TF, Wu NL, Hampton M, Krell J, Rich P, Blauvelt A, Pariser D, Adsit S, Takahashi S, Sofen H, Tichy E, Cather J, Tyring S, Jarratt M, Jones T, Tu J, Kircik L, Gelfand J, Helfrich Y, Swinyer L, Kivitz A, Horowitz D, Klas P, Elewski B, Weiss J, Schlessinger J, Samady J, Menter A, Jazayeri S, Moore J, Marmur E, Fowler J, Sperber B, Giessel M, Kogan N, Edgardo C, Cabrera H, Rodriguez É, Magariños G, Ricardo G, Viviana P, Sinclair R, Foley P, Spelman L, Shumack S, Nikkels AF, Ghislain PD, Roseeuw D, Gent UZ, Lambert J, Poulin Y, Langley R, Albrecht L, Papp K, Lynde C, Ho V, Wasel N, Raman M, Jaller A, Gonzalez C, Peñaranda E, Hamza A, Reitamo S, Koulu L, Ruer-Mulard M, Grob JJ, Paul C, Ortonne JP, Beylot M, Reguiai Z, Bachelez H, Philip S, Grigat C, Zahn E, Niesmann J, Mößner R, Ockefels HM, Herbst R, Chalid A, Lutz K, Pauser S, Podda M, Schultz E, Szeimies RM, Stratmann L, Paschen C, Georg P, Ekanayake-Bohlig S, Simon M, Reich K, Kaatz M, Effendy I, Weidinger S, Haase I, Dirschka T, Thaci D, Wilsmann-Theis D, Sticherling M, Schäkel K, Mrowietz U, Luger T, Karrer S, Biedermann T, Wozel G, Stine L, Schadendorf D, Bran G, Hernandez MA, Bewley A, Manrique Mdel P, Rivas E, Urquizu P, Sigurgeirsson B, Remenyik É, Vajda A, Battyani Z, Telegdy E, Apostol E, Károlyi Z, Kemény L, Mubashir AM, Bhat R, Maragondanahalli G, Dhurat R, Budamakuntla L, Putta S, Gupta S, Pande S, Aradhya SS, Magnoni C, Potenza C, Peris K, Micali G, Ayala F, Dofitas B, Mendinueto-Salvador J, Narbutt J, Adamski Z, Szepietowski J, Kaszuba A, Poenaru M, Olsavszky R, Cavaropol L, Giurceanu C, Aw D, Choi JH, Lee JH, Lee S, Seo SJ, Kim KJ, Choe Y, Kim MB, Lee JH, Lee MG, Kim TY, Vanaclocha F, Puig L, Carazo JS, Dobao Pde L, Gil Rdel R, Chico NF, Virtanen M, Eriksson T, Flytström I, Svensson Å, Walker B, Brudnik U, Berth-Jones J, Ladoyanni E, Griffiths C, Wachsmuth R, Wagaman K, Frankel E, Fretzin S, Mader R, Davis S, Draelos Z, Pelle M, Rich P, Pariser DM, Bystol N, Adsit S, Miller S, Krell J, Kogan N, Edgardo C, Cabrera H, Rodriguez É, Magariños G, Ricardo G, Viviana P, Sinclair R, Foley P, Spelman L, Shumack S, Nikkels AF, Ghislain PD, Roseeuw D, Lambert J, Poulin Y, Langley R, Albrecht L, Papp K, Lynde C, Ho V, Wasel N, Raman M, Jaller A, Gonzalez C, Peñaranda E, Hamza A, Reitamo S, Koulu L, Ruer-Mulard M, Grob JJ, Paul C, Ortonne JP, Barry MB, Reguiai Z, Bachelez H, Philip S, Grigat C, Zahn E, Niesmann J, Mößner R, Ockefels HM, Herbst R, Chalid A, Lutz K, Pauser S, Podda M, Schultz E, Szeimies RM, Stratmann L, Paschen C, Georg P, Ekanayake-Bohlig S, Simon M, Reich K, Kaatz M, Effendy I, Weidinger S, Haase I, Dirschka T, Thaci D, Wilsmann-Theis D, Sticherling M, Schäkel K, Mrowietz U, Luger T, Karrer S, Biedermann T, Wozel G, Stine L, Schadendorf D, Bran G, Hernandez MA, Manrique Mdel P, Rivas E, Urquizu P, Sigurgeirsson B, Remenyik É, Vajda A, Battyani Z, Telegdy E, Apostol E, Károlyi Z, Kemény L, Mubashir AM, Saple D, Bhat R, Maragondanahalli G, Dhurat R, Budamakuntla L, Putta S, Gupta S, Pande S, Aradhya SS, Magnoni C, Potenza C, Peris K, Micali G, Ayala F, Dofitas B, Mendinueto-Salvador J, Narbutt J, Adamski Z, Szepietowski J, Kaszuba A, Poenaru M, Olsavszky R, Cavaropol L, Giurceanu C, Aw D, Choi JH, Lee JH, Lee S, Seo SJ, Kim KJ, Choe Y, Kim MB, Lee JH, Lee MG, Kim TY, Vanaclocha F, Puig L, Carazo JS, Dobao Pde L, Gil Rdel R, Chico NF, Virtanen M, Eriksson T, Flytström I, Svensson Å, Walker B, Brudnik U, Berth-Jones J, Ladoyanni E, Griffiths C, Bewley A, Wachsmuth R, Wagaman K, Frankel E, Fretzin S, Mader R, Davis S, Draelos Z, Pelle M, Rich P, Pariser DM, Bystol N, Adsit S, Miller S, Krell J (2014) Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 371: 326-38.

Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371: 1867-76.

Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU (2014) Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 15: 436-44.

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Sileni VC, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K (2014) Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med : .

McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O’Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15: 323-32.

Skabytska Y, Wölbing F, Günther C, Köberle M, Kaesler S, Chen KM, Guenova E, Demircioglu D, Kempf WE, Volz T, Rammensee HG, Schaller M, Röcken M, Götz F, Biedermann T (2014) Cutaneous Innate Immune Sensing of Toll-like Receptor 2-6 Ligands Suppresses T Cell Immunity by Inducing Myeloid-Derived Suppressor Cells. Immunity 41: 762-75.

Ulmer A, Dietz K, Hodak I, Polzer B, Scheitler S, Yildiz M, Czyz Z, Lehnert P, Fehm T, Hafner C, Schanz S, Röcken M, Garbe C, Breuninger H, Fierlbeck G, Klein CA (2014) Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. PLoS Med 11: e1001604.

Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzer U, Loquai C, Weide B, Hassel JC, Gabriel SB, Carter SL, Getz G, Garraway LA, Schadendorf D, Dermatologic Cooperative Oncology Group of Germany (DeCOG) (2014) The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discov 4: 94-109.

Braumueller Heidi, Wieder Thomas, Brenner Ellen, Assmann Sonja, Hahn Matthias, Alkhaled Mohammed, Schilbach Karin, Essmann F, Kneilling Manfred, Griessinger Christoph, Ranta Felicia, Ullrich Susanne, Mocikat Ralph, Braungart Kilian, Mehra Tarun, Fehrenbacher Birgit, Berdel Julia, Niessner Heike, Meier Friedegund, van den Broek Maries, Haering Hans-Ulric, Handgretinger Rupert, Quintanilla-Martinez Leticia, Fend Falko, Pesic Marina, Bauer Juergen, Zender Lars, Schaller Martin, Schulze-Osthoff K, Roecken Martin (2013) T-helper-1-cell cytokines drive cancer into senescence Nature 494: 361-365.

Fischer J, Teufel M, Feidt A, Giel KE, Zipfel S, Biedermann T (2013) Tolerated wasp sting challenge improves health-related quality of life in patients allergic to wasp venom. J Allergy Clin Immunol 132: 489-90.

O’Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J, Friedlander P, Garbe C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, Hauschild A (2013) Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol 31: 1211-8.

Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31: 616-22.

nach oben